Guillain–Barré syndrome following coronavirus disease vaccine: First report from Nepal
oleh: Prajjwol Luitel, Bibek Poudel, Devansh Upadhyay, Sujan Paudel, Nishan Tiwari, Bikram Prasad Gajurel, Ragesh Karn, Reema Rajbhandari, Aashish Shrestha, Niraj Gautam, Rajeev Ojha
| Format: | Article |
|---|---|
| Diterbitkan: | SAGE Publishing 2022-05-01 |
Deskripsi
ChAdOx1 nCoV-19 is an effective and well-tolerated coronavirus disease 2019 vaccine. However, rare cases of serious adverse events have been reported with it. We report a patient who did not have active or prior coronavirus disease 2019 infection, who developed Guillain–Barré syndrome 7 days following the first dose of ChAdOx1 nCoV-19 vaccination. He was treated with intravenous immunoglobulin, with stabilization of the disease. Proper monitoring and prompt reporting of such cases are required to ensure the safety of the vaccine.